Real world evidence from the Spanish MAB-MIG registry also suggest that patients are reaching anti-CGRP mAbs only after a long time under treatment and after more lines of treatment than those recommended: on average, the 210 migraine patients who had completed at least 12 weeks of erenumab treatment had failed a mean of 7.8 preventive treatments at baseline (including BoNT/A in 95.2% of patients) [17]. Here, CALCA is linked to migraine disorder.